---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-26-000094"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2026-08-04T11:02:43+00:00"
generated_at: "2026-08-04T11:05:28.345760+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pfizer Q2 2026: Revenue $15.0B, raises FY guidance midpoint by $500M, reports net loss on $4.3B impairments

## Summary
- Q2 revenue $15.0B (+1% operational); launched/acquired products grew 18% operationally.
- Reported net loss $248M ($0.04 LPS) from $4.3B impairments; adjusted EPS $0.77 flat YoY.
- Raises FY2026 revenue guidance to $60.5-$62.5B (midpoint +$500M); reaffirms adjusted EPS $2.80-$3.00.
- Announces additional $2.5B in productivity savings from 2027-2029; ongoing cost realignment program.
- Pipeline: Lorbrena 7-yr PFS HR 0.19, Padcev MIBC approval, Litfulo vitiligo Phase 3 positive, sigvotatug vedotin miss.

## SEC filing metadata
- accession: 0000078003-26-000094
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2026-08-04T11:02:43+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/0000078003-26-000094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-26-000094
- JSON: https://secwatch.observer/filing/0000078003-26-000094.json
- Plain text: https://secwatch.observer/filing/0000078003-26-000094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.